Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.

Puerto Rico health sciences journal - 1 Sept 2017

Martes-Martinez Carlos, Méndez-Sepúlveda Cristian, Millán-Molina Joel, French-Kim Matthew, Marín-Centeno Heriberto, Rivera-Miranda Giselle C, Hernández-Muñoz José J, Duconge-Soler Jorge

Abstract excerpt

OBJECTIVE: To evaluate the cost-utility of the pharmacogenetic-guided dosing of warfarin (PGx), when compared to the current dosing strategy. METHODS: A Markov model was developed to assess the impact of the genotypingguided warfarin dosing in a hypothetical cohort of patients. The model was based on the percentage of time patients spent within the therapeutic international normalized ratio (INR) range (PTTR)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to International Normalized Ratio

Share to Markov Chains

Share to Puerto Rico

Share to Quality-Adjusted Life Years

Share to Veterans

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 28915306
PMCID: PMC5993426

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.PMID 28915306Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.Semantic proximity Read ↗

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Semantic proximity Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.Semantic proximity Read ↗

Cost-Effectiveness of Genotype-Guided Acenocoumarol Therapy in Atrial Fibrillation: A Pharmacogenomic Simulation Study in the Chilean PopulationSemantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.